MedTrace Logo

Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.

NCT05695781 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 740

Last updated 2024-07-11

No results posted yet for this study

Summary

The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for the treatment of the signs and symptoms of dry eye disease.

Conditions

Interventions

DRUG

BRM421 Ophthalmic Solution

A topical drop of BRM421 ophthalmic solution.

DRUG

Vehicle

A topical drop of vehicle (minus active) ophthalmic solution.

Sponsors & Collaborators

  • BRIM Biotechnology Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2023-12-30
Completion
2024-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05695781 on ClinicalTrials.gov